EGFR and neoplasm: Altogether, these results highlight i) the different tumor responses against the EGFR TKI erlotinib and osimerinib and against bevacizumab for A549, PC9 and H1975 tumors and ii) demonstrate the efficacy of osimertinib plus bevacizumab in some NSCLC subpopulation.